Is it necessary to take Sotolaxib for a long time?

Sotorasib is an oral small molecule inhibitor targeting the KRAS G12C mutation. It is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) after treatment. As a targeted therapy drug, sotorasibu inhibits tumor development by selectively inhibiting the mutated KRAS protein and blocking the growth signals of tumor cells. Since KRAS mutations have always been considered an "undruggable" problem, the launch of sotorasib has brought new treatment hope to this type of patients.

In clinical applications, sotoraxib usually requires long-term continuous administration. The goal of treatment is not only to quickly shrink tumors, but more importantly, to delay disease progression and maintain treatment effects. Doctors generally recommend continuing to take sotorasib as long as the patient tolerates the drug and the disease does not progress significantly. Only if the tumor is found to progress significantly or unacceptable adverse reactions occur during the medication, discontinuation of the medication or adjustment of the treatment plan will be considered.

During long-term use of sotoraxib, patients may experience some side effects, such as diarrhea, nausea, fatigue, elevated transaminases, etc. In most cases, these side effects can be treated through symptomatic treatment or short-term drug withdrawal and adjustment. In addition, while taking sotorasiib, regular imaging examinations (such as CT scans) are required to evaluate the efficacy, and at the same time monitor liver function and other indicators to ensure the safety and effectiveness of the medication.

Generally speaking, the treatment approach of sotorasiib emphasizes the combination of long-term management and disease monitoring. Continuous use can not only help patients control their disease to the greatest extent, but may also extend progression-free survival (PFS) and overall survival (OS). Of course, whether to take it for a long time still needs to be decided based on individual treatment response, tolerance and doctor’s evaluation.

Reference materials:https://www.lumakras.com/